5/10, 3:33 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Novavax

Novavax says its COVID/flu vaccine combo shows promise

Novavax, Inc. announced on Monday that its NanoFlu/NVX-CoV2373 vaccine combination, meant to protect against both the seasonal flu and COVID-19 at the same time, showed optimistic results in the preclinical trial.

The combination consists of a quadrivalent influenza vaccine, and a "recombinant SARS-COV-2 spike protein," the company said in a statement, claiming that "robust" immune responses to both COVID and flu encouraged the pharmaceutical firm to start the next phase of the trial before the end of the year.

"Despite low rates during the COVID-19 pandemic, influenza remains a significant risk to global public health and the need for versatile, more effective vaccines is as important as ever, including against the flu. This study's results build on our success to-date with NVX-CoV2373, and with NanoFlu, which successfully achieved all of its objectives in a pivotal Phase 3 trial announced last year," Gregory Glen, president of research and development at Novavax, commented.

Breaking the News / BU